Screener
BridgeBio Pharma BBIO Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $879,891 | $570,119 |
| Marketable securities | 60,295 | 17,363 |
| Accounts receivable, net | 205,226 | 139,444 |
| Inventories | 32,980 | 26,753 |
| Prepaid expenses and other current assets | 62,914 | 44,070 |
| Total current assets | 1,241,306 | 797,749 |
| Equity method investments | 61,529 | 79,972 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's accounts receivable?
- BridgeBio Pharma (BBIO) reported accounts receivable of $205.23M in Q1 2026.
- How has BridgeBio Pharma's accounts receivable changed year-over-year?
- BridgeBio Pharma's accounts receivable increased by 78.0% year-over-year, from $115.27M to $205.23M.
- What is the long-term trend for BridgeBio Pharma's accounts receivable?
- Over 3 years (2022 to 2025), BridgeBio Pharma's accounts receivable has grown at a 232.5% compound annual growth rate (CAGR), from -$3.79M to $139.44M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about BridgeBio Pharma's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude